TY - JOUR
T1 - Intravenous maintenance fluid therapy in acutely and critically ill children: state of the evidence
AU - Brossier, David W
AU - Goyer, Isabelle
AU - Verbruggen, Sascha C A T
AU - Jotterand Chaparro, Corinne
AU - Rooze, Shancy
AU - Marino, Luise V
AU - Schlapbach, Luregn J
AU - Tume, Lyvonne N
AU - Valla, Frederic V
N1 - Copyright © 2024 Elsevier Ltd. All rights reserved.
PY - 2024/3/31
Y1 - 2024/3/31
N2 - Intravenous maintenance fluid therapy (IV-MFT) is one of the most prescribed, yet one of the least studied, interventions in paediatric acute and critical care settings. IV-MFT is not typically treated in the same way as drugs with specific indications, contraindications, compositions, and associated adverse effects. In the last decade, societies in both paediatric and adult medicine have issued evidence-based practice guidelines for the use of intravenous fluids in clinical practice. The main objective of this Viewpoint is to summarise and compare the rationales on which these international expert guidelines were based and how these recommendations affect IV-MFT practices in paediatric acute and critical care. Although these guidelines recommend the use of isotonic fluids as a standard in IV-MFT, some discrepancies and uncertainties remain regarding the systematic use of balanced fluids, glucose and electrolyte requirements, and appropriate fluid volume. IV-MFT should be considered in the same way as any other prescription drug and none of the components of IV-MFT prescription should be overlooked (ie, choice of drug, dosing rate, duration of treatment, and de-escalation). Furthermore, most evidence that was used to inform the guidelines comes from high-income countries. Although some principles of IV-MFT are universal, the direct relevance to and feasibility of implementing the guidelines in low-income and middle-income countries is uncertain. [Abstract copyright: Copyright © 2024 Elsevier Ltd. All rights reserved.]
AB - Intravenous maintenance fluid therapy (IV-MFT) is one of the most prescribed, yet one of the least studied, interventions in paediatric acute and critical care settings. IV-MFT is not typically treated in the same way as drugs with specific indications, contraindications, compositions, and associated adverse effects. In the last decade, societies in both paediatric and adult medicine have issued evidence-based practice guidelines for the use of intravenous fluids in clinical practice. The main objective of this Viewpoint is to summarise and compare the rationales on which these international expert guidelines were based and how these recommendations affect IV-MFT practices in paediatric acute and critical care. Although these guidelines recommend the use of isotonic fluids as a standard in IV-MFT, some discrepancies and uncertainties remain regarding the systematic use of balanced fluids, glucose and electrolyte requirements, and appropriate fluid volume. IV-MFT should be considered in the same way as any other prescription drug and none of the components of IV-MFT prescription should be overlooked (ie, choice of drug, dosing rate, duration of treatment, and de-escalation). Furthermore, most evidence that was used to inform the guidelines comes from high-income countries. Although some principles of IV-MFT are universal, the direct relevance to and feasibility of implementing the guidelines in low-income and middle-income countries is uncertain. [Abstract copyright: Copyright © 2024 Elsevier Ltd. All rights reserved.]
KW - Child
KW - Critical Care
KW - Critical Illness/therapy
KW - Fluid Therapy/adverse effects
KW - Humans
KW - Infusions, Intravenous
KW - Poverty
UR - http://www.scopus.com/inward/record.url?scp=85182669431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85182669431&partnerID=8YFLogxK
U2 - 10.1016/S2352-4642(23)00288-2
DO - 10.1016/S2352-4642(23)00288-2
M3 - Review article
C2 - 38224704
SN - 2352-4642
SN - 2352-4650
VL - 8
SP - 236
EP - 244
JO - The Lancet. Child & adolescent health
JF - The Lancet. Child & adolescent health
IS - 3
ER -